Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology-Part 1: acute coronary syndromes and acute pericardial diseases.
Gevaert, Sofie A; Halvorsen, Sigrun; Sinnaeve, Peter Ret al.
2021 • In European Heart Journal. Acute Cardiovascular Care, 10 (8), p. 947-959
[en] Advances in treatment, common cardiovascular (CV) risk factors and the ageing of the population have led to an increasing number of cancer patients presenting with acute CV diseases. These events may be related to the cancer itself or the cancer treatment. Acute cardiac care specialists must be aware of these acute CV complications and be able to manage them. This may require an individualized and multidisciplinary approach. We summarize the most common acute CV complications of cytotoxic, targeted, and immune-based therapies. This is followed by a proposal for a multidisciplinary approach where acute cardiologists work close together with the treating oncologists, haematologists, and radiation specialists, especially in situations where immediate therapeutic decisions are needed. In this first part, we further focus on the management of acute coronary syndromes and acute pericardial diseases in patients with cancer.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Gevaert, Sofie A ; Department of Cardiology, Ghent University Hospital, C Heymanslaan 10, 9000 Gent
Halvorsen, Sigrun; Department of Cardiology, Oslo University Hospital Ulleval and University of
Sinnaeve, Peter R; Department of Cardiology, University Hospital Leuven, Herestraat 49, 3000 Leuven,
Sambola, Antonia; Department of Cardiology, University Hospital Vall d'Hebron, Universitat
Gulati, Geeta; Department of Cardiology, Oslo University Hospital Ulleval and University of
LANCELLOTTI, Patrizio ; Centre Hospitalier Universitaire de Liège - CHU > > Service de cardiologie
Van Der Meer, Peter; Department of Cardiology, University of Groningen University Medical Center
Lyon, Alexander R; Cardio-Oncology Clinic at Royal Brompton Hospital and Imperial College, Sydney
Farmakis, Dimitrios; University of Cyprus Medical School, Agio Nikolaou street 93, 2408 Nicosia,
Lee, Geraldine; Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King's
Boriani, Giuseppe ; Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences
Wechalekar, Ashutosh; Department of Haematology, University College London/University College London
Okines, Alicia; Department of Medicine, The Royal Marsden NHS Foundation Trust, Fulham road 203,
Asteggiano, Riccardo ; Insubria University, Via Ravasi 2, 21100 Varese, Italy. ; LARC (Laboratorio Analisi e Ricerca Clinica), Via Mombarcaro 80, 10136 Turin
Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology-Part 1: acute coronary syndromes and acute pericardial diseases.
Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation 2016;133:1104-1114.
Zamorano JL, Lancellotti P, Rodriguez Mu~noz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM; ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016;37:2768-2801.
Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol 2020;17:474-502.
Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Elkind MSV, Panageas KS, DeAngelis LM. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol 2017;70:926-938.
Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, Herrmann J, Porter C, Lyon AR, Lancellotti P, Patel A, DeCara J, Mitchell J, Harrison E, Moslehi J, Witteles R, Calabro MG, Orecchia R, de Azambuja E, Zamorano JL, Krone R, Iakobishvili Z, Carver J, Armenian S, Ky B, Cardinale D, Cipolla CM, Dent S, Jordan K; ESMO Guidelines Committee. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol 2020;31:171-190.
Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, Tocchetti CG, Moslehi J, Groarke JD, Bergler-Klein J, Khoo V, Tan LL, Anker MS, von Haehling S, Maack C, Pudil R, Barac A, Thavendirnathan P, Ky B, Neilan TG, Belenkov Y, Rosen SD, Iakobishvili Z, Sverdlov AL, Hajjar LA, Macedo AVS, Manisty C, Ciardiello F, Farmakis D, De Boer RA, Skouri H, Suter TM, Cardinale D, Witteles RM, Fradley MG, Herrmann J, Cornell RF, Wechelaker A, Mauro MJ, Milojkovic D, de Lavallade H, Ruschitzka F, Coats AJS, Seferovic PM, Chioncel O, Thum T, Bauersachs J, Andres MS, Wright DJ, Lopez-Fernandez T, Plummer C, Lenihan D. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a Position Statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail 2020; 22:1945-1960.
Claeys MJ, Roubille F, Casella G, Zukermann R, Nikolaou N, De Luca L, Gierlotka M, Iakobishvili Z, Thiele H, Koutouzis M, Sionis A, Monteiro S, Beauloye C, Held C, Tint D, Zakke I, Serpytis P, Babic Z, Belohlavev, J, Magdy A, Sivagowry Rasalingam M, Daly K, Arroyo D, Vavlukis M, Radovanovic N, Trendafilova E, Marandi T, Hassager C, Lettino M, Price S, Bonnefoy E. Organization of intensive cardiac care units in Europe: results of a multinational survey. Eur Heart J Acute Cardiovasc Care 2020;9:993-1001.
Lancellotti P, Suter TM, López-Fernández T, Galderisi M, Lyon AR, Van der Meer P, Cohen Solal A, Zamorano J-L, Jerusalem G, Moonen M, Aboyans V, Bax JJ, Asteggiano R. Cardio-Oncology Services: rationale, organization, and implementation. Eur Heart J 2019;40:1756-1763.
Bharadwaj A, Potts J, Mohamed MO, Parwani P, Swamy P, Lopez-Mattei JC, Rashid M, Kwok CS, Fischman DL, Vassiliou VS, Freeman P, Michos ED, Mamas MA.. Acute myocardial infarction treatments and outcomes in 6.5 million patients with a current or historical diagnosis of cancer in the USA. Eur Heart J 2019;41: 2183-2193.
Anand AJ. Fluorouracil cardiotoxicity. Ann Pharmacother 1994;28:374-378.
Desai MY, Jellis CL, Kotecha R, Johnston DR, Griffin BP. Radiation-associated cardiac disease: a practical approach to diagnosis and management. JACC Cardiovasc Imaging 2018;11:1132-1149.
Darby SC, Cutter DJ, Boerma M, Constine LS, Fajardo LF, Kodama K, Mabuchi K, Marks LB, Mettler FA, Pierce LJ, Trott KR, Yeh ETH, Shore RE. Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys 2010;76:656-665.
Demers M, Krause DS, Schatzberg D, Martinod K, Voorhees JR, Fuchs TA, Scadden DT, Wagner DD. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci USA 2012;109:13076-13081.
Pineda AM, Mihos CG, Nascimento FO, Santana O, Lamelas J, Beohar N. Coronary embolization from a left atrial myxoma containing malignant lymphoma cells. Tex Heart Inst J 2015;42:565-568.
Harris S, Waddell J. Non-Hodgkin's lymphoma: an unusual cause of myocardial infarction and hypercalcaemia. Clin Oncol (R Coll Radiol) 1993;5:189-190.
Collet JP, Thiele H, Barbato E, Barthelemy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, Juni P, Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten FH, Sibbing D, Siontis GCM, E. S. C. Scientific Document Group.. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021;42:2020-2021.
Yusuf SW, Daraban N, Abbasi N, Lei X, Durand JB, Daher IN. Treatment and outcomes of acute coronary syndrome in the cancer population. Clin Cardiol 2012;35:443-450.
Giza DE, Boccalandro F, Lopez-Mattei J, Iliescu G, Karimzad K, Kim P, Iliescu C. Ischemic heart disease: special considerations in cardio-oncology. Curr Treat Options Cardiovasc Med 2017;19:37.
Mohamed MO, Van Spall HGC, Kontopantelis E, Alkhouli M, Barac A, Elgendy IY, Khan SU, Kwok CS, Shoaib A, Bhatt DL, Mamas MA. Effect of primary percutaneous coronary intervention on in-hospital outcomes among active cancer patients presenting with ST-elevation myocardial infarction: a propensity score matching analysis. Eur Heart J Acute Cardiovasc Care 2021.
Ueki Y, Vö geli B, Karagiannis A, Zanchin T, Zanchin C, Rhyner D, Otsuka T, Praz F, Siontis GCM, Moro C, Stortecky S, Billinger M, Valgimigli M, Pilgrim T, Windecker S, Suter T, Räber L. Ischemia and bleeding in cancer patients undergoing percutaneous coronary intervention. JACC CardioOncol 2019;1:145-155.
Potts JE, Iliescu CA, Lopez Mattei JC, Martinez SC, Holmvang L, Ludman P, De Belder MA, Kwok CS, Rashid M, Fischman DL, Mamas MA. Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States. Eur Heart J 2019;40:1790-1800.
Velders MA, Boden H, Hofma SH, Osanto S, van der Hoeven BL, Heestermans AACM, Cannegieter SC, Jukema JW, Umans VAWM, Schalij MJ, van Boven AJ. Outcome after ST elevation myocardial infarction in patients with cancer treated with primary percutaneous coronary intervention. Am J Cardiol 2013;112: 1867-1872.
Guddati AK, Joy PS, Kumar G. Analysis of outcomes of percutaneous coronary intervention in metastatic cancer patients with acute coronary syndrome over a 10-year period. J Cancer Res Clin Oncol 2016;142:471-479.
van Werkum JW, Heestermans AA, Zomer AC, Kelder JC, Suttorp M-J, Rensing BJ, Koolen JJ, Brueren BRG, Dambrink J-HE, Hautvast RW, Verheugt FW, ten Berg JM. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol 2009;53:1399-1409.
Iliescu CA, Grines CL, Herrmann J, Yang EH, Cilingiroglu M, Charitakis K, Hakeem A, Toutouzas KP, Leesar MA, Marmagkiolis K. SCAI Expert consensus statement: evaluation, management, and special considerations of cardiooncology patients in the cardiac catheterization laboratory (endorsed by the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia intervencionista). Catheter Cardiovasc Interv 2016;87:E202-E223.
Iannaccone M, D'Ascenzo F, Vadalà P, Wilton SB, Noussan P, Colombo F, Raposeiras Roubín S, Abu Assi E, González-Juanatey JR, Simao Henriques JP, Saucedo J, Kikkert WJ, Nu~nez-Gil I, Ariza-Sole A, Song X-T, Alexopoulos D, Liebetrau C, Kawaji T, Moretti C, Garbo R, Huczek Z, Nie S-P, Fujii T, Correia LCL, Kawashiri M-A, Garciá Acu~na JM, Southern D, Alfonso E, Terol B, Garay A, Zhang D, Chen Y, Xanthopoulou I, Osman N, Möllmann H, Shiomi H, Giordana F, Kowara M, Filipiak K, Wang X, Yan Y, Fan J-Y, Ikari Y, Nakahashi T, Sakata K, Gaita F, Yamagishi M, Kalpak O, Kedev S. Prevalence and outcome of patients with cancer and acute coronary syndrome undergoing percutaneous coronary intervention: a BleeMACS substudy. Eur Heart J Acute Cardiovasc Care 2018;7: 631-638.
Valgimigli M, Bueno H, Byrne RA, Collet J-P, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann F-J, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN; ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018;39:213-260.
Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim H-S, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice M-C. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J 2019;40:2632-2653.
Sarkiss MG, Yusuf SW, Warneke CL, Botz G, Lakkis N, Hirch-Ginsburg C, Champion JC, Swafford J, Shaw ADS, Lenihan DJ, Durand J-B. Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes. Cancer 2007;109:621-627.
Oren O, Herrmann J. Arterial events in cancer patients-the case of acute coronary thrombosis. J Thorac Dis 2018;10:S4367-S4385.
Yetis Sayin B, Oto MA. Acute coronary syndrome in cancer patients. Am J Cardiovasc Drugs 2018;18:361-372.
Ganatra S, Sharma A, Levy MS. Re-evaluating the safety of drug-eluting stents in cancer patients. JACC Cardiovasc Interv 2017;10:2334-2337.
Agnelli G, Becattini C, Meyer G, Mu~noz A, Huisman MV, Connors JM, Cohen A, Bauersachs R, Brenner B, Torbicki A, Sueiro MR, Lambert C, Gussoni G, Campanini M, Fontanella A, Vescovo G, Verso M. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl JMed 2020;382:1599-1607.
Hokusai VTEI, Buller HR, Decousus H. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl JMed 2013;369:1406-1415.
Liebman HA. Thrombocytopenia in cancer patients. Thromb Res 2014; 133(Suppl 2):S63-S69.
Iliescu C, Balanescu DV, Donisan T, Giza DE, Mu~noz Gonzalez ED, Cilingiroglu M, Song J, Mukerji SS, Lopez-Mattei JC, Kim PY, Palaskas N, Mouhayar EN, Durand J-B, Marmagkiolis K. Safety of diagnostic and therapeutic cardiac catheterization in cancer patients with acute coronary syndrome and chronic thrombocytopenia. Am J Cardiol 2018;122:1465-1470.
Cianci G, Morelli MF, Cannita K, Morese R, Ricevuto E, Di Rocco ZC, Porzio G, Lanfiuti Baldi P, Ficorella C. Prophylactic options in patients with 5-fluorouracilassociated cardiotoxicity. Br J Cancer 2003;88:1507-1509.
Ambrosy AP, Kunz PL, Fisher GA, Witteles RM. Capecitabine-induced chest pain relieved by diltiazem. Am J Cardiol 2012;110:1623-1626.
Akpek G, Hartshorn KL. Failure of oral nitrate and calcium channel blocker therapy to prevent 5-fluorouracil-related myocardial ischemia: a case report. Cancer Chemother Pharmacol 1999;43:157-161.
Clasen SC, Ky B, O'Quinn R, Giantonio B, Teitelbaum U, Carver JR. Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigm. J Gastrointest Oncol 2017;8:970-979.
Khosrow-Khavar F, Bouganim N, Filion KB, Suissa S, Azoulay L. Cardiotoxicity of sequential aromatase inhibitors use in women with breast cancer. Am J Epidemiol 2020;28:487-496.
Khosrow-Khavar F, Filion KB, Al-Qurashi S, Torabi N, Bouganim N, Suissa S, Azoulay L. Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 2017;28:487-496.
Burazor I, Imazio M, Markel G, Adler Y. Malignant pericardial effusion. Cardiology 2013;124:224-232.
Sánchez-Enrique C, Nu~nez-Gil IJ, Viana-Tejedor A, De Agustín A, Vivas D, Palacios-Rubio J, Vilchez JP, Cecconi A, Macaya C, Fernández-Ortiz A. Cause and long-term outcome of cardiac tamponade. Am J Cardiol 2016;117:664-669.
Burazor I, Aviel-Ronen S, Imazio M, Markel G, Grossman Y, Yosepovich A, Adler Y. Primary malignancies of the heart and pericardium. Clin Cardiol 2014;37: 582-588.
Bottinor WJ, Migliore CK, Lenneman CA, Stoddard MF. Echocardiographic assessment of cardiotoxic effects of cancer therapy. Curr Cardiol Rep 2016;18:99.
Ning MS, Tang L, Gomez DR, Xu T, Luo Y, Huo J, Mouhayar E, Liao Z. Incidence and predictors of pericardial effusion after chemoradiation therapy for locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2017;99:70-79.
Wang K, Eblan MJ, Deal AM, Lipner M, Zagar TM, Wang Y, Mavroidis P, Lee CB, Jensen BC, Rosenman JG, Socinski MA, Stinchcombe TE, Marks LB. Cardiac toxicity after radiotherapy for stage III non-small-cell lung cancer: pooled analysis of dose-escalation trials delivering 70 to 90 Gy. J Clin Oncol 2017;35:1387-1394.
Takata N, Kataoka M, Hamamoto Y, Tsuruoka S, Kanzaki H, Uwatsu K, Nagasaki K, Mochizuki T. Risk factors for pericardial effusion after chemoradiotherapy for thoracic esophageal cancer-comparison of four-field technique and traditional two opposed fields technique. J Radiat Res 2018;59:291-297.
Adler Y, Charron P, Imazio M, Badano L, Baró n-Esquivias G, Bogaert J, Brucato A, Gueret P, Klingel K, Lionis C, Maisch B, Mayosi B, Pavie A, Ristic AD, Sabaté Tenas M, Seferovic P, Swedberg K, Tomkowski W; ESC Scientific Document Group. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: the Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2015; 36:2921-2964.
Jordan JH, Todd RM, Vasu S, Hundley WG. Cardiovascular magnetic resonance in the oncology patient. JACC Cardiovasc Imaging 2018;11:1150-1172.
Strobbe A, Adriaenssens T, Bennett J, Dubois C, Desmet W, McCutcheon K, Van Cleemput J, Sinnaeve PR. Etiology and long-term outcome of patients undergoing pericardiocentesis. J Am Heart Assoc 2017;6:e007598.
Patel N, Rafique AM, Eshaghian S, Mendoza F, Biner S, Cercek B, Siegel RJ. Retrospective comparison of outcomes, diagnostic value, and complications of percutaneous prolonged drainage versus surgical pericardiotomy of pericardial effusion associated with malignancy. Am J Cardiol 2013;112: 1235-1239.
Kazantzis T, Bibas BJ, Dela-Vega AJ, Nabuco P, Lauricella LL, Pêgo-Fernandes PM, Terra RM. Predictors of hospital discharge in cancer patients with pericardial effusion undergoing surgical pericardial drainage. J Surg Oncol 2019;119:143-147.
Sinnaeve PR, Adriaenssens T. A contemporary look at pericardiocentesis. Trends Cardiovasc Med 2019;29:375-383.
Zhang J, Zhang Q, Chen X, Zhang N. Management of neoplastic pericardial disease. Herz 2020;45:46-51.
Irazusta FJ, Jiménez-Valero S, Gemma D, Meras P, Galeote G, Sanchez-Recalde A, Rial V, Moreno R, Lopez-Sendon JL. Percutaneous balloon pericardiotomy: treatment of choice in patients with advanced oncological disease and severe pericardial effusion. Cardiovasc Revasc Med 2017;18:S14-S17.
Labbe C, Tremblay L, Lacasse Y. Pericardiocentesis versus pericardiotomy for malignant pericardial effusion: a retrospective comparison. Curr Oncol 2015;22: 412-416.
Palaskas N, Morgan J, Daigle T, Banchs J, Durand J-B, Hong D, Naing A, Le H, Hassan SA, Karimzad K, Mouhayar E, Kim P, Lopez-Mattei J, Thompson K, Yusuf SW, Iliescu C. Targeted cancer therapies with pericardial effusions requiring pericardiocentesis focusing on immune checkpoint inhibitors. Am J Cardiol 2019;123: 1351-1357.
Salem J-E, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano J-P, Balko JM, Bonaca MP, Roden DM, Johnson DB, Moslehi JJ. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 2018;19: 1579-1589.
Saab J, Hoda RS, Narula N, Hoda SA, Geraghty BE, Nasar A, Alperstein SA, Port JL, Giorgadze T. Diagnostic yield of cytopathology in evaluating pericardial effusions: clinicopathologic analysis of 419 specimens. Cancer Cytopathol 2017;125: 128-137.
Imazio M, Colopi M, De Ferrari GM. Pericardial diseases in patients with cancer: contemporary prevalence, management and outcomes. Heart 2020;106:569-574.
Rooper LM, Ali SZ, Olson MT. A minimum volume of more than 60 ml is necessary for adequate cytologic diagnosis of malignant pericardial effusions. Am J Clin Pathol 2016;145:101-106.
Karatolios K, Pankuweit S, Maisch B. Diagnostic value of biochemical biomarkers in malignant and non-malignant pericardial effusion. Heart Fail Rev 2013;18: 337-344.
Maggiolini S, De Carlini CC, Ferri LA, Colombo GI, Gentile G, Meles E, Riva B, Casella TC, Imazio M, Brucato A. The role of early contrast-enhanced chest computed tomography in the aetiological diagnosis of patients presenting with cardiac tamponade or large pericardial effusion. Eur Heart J Cardiovasc Imaging 2016;17:421-428.
Defruyt L, Ozpak E, Gevaert S, Buyzere MD, Van decasteele E, Pauw MD, Tromp F. Malignant cardiac tamponade: safety and efficacy of intrapericardial bleomycin instillation. Acta Clin Belg 2020;1-8.
Virk SA, Chandrakumar D, Villanueva C, Wolfenden H, Liou K, Cao C. Systematic review of percutaneous interventions for malignant pericardial effusion. Heart 2015;101:1619-1626.
Liu G, Crump M, Goss PE, Dancey J, Shepherd FA. Prospective comparison of the sclerosing agents doxycycline and bleomycin for the primary management of malignant pericardial effusion and cardiac tamponade. J Clin Oncol 1996;14:3141-3147.
Lestuzzi C, Bearz A, Lafaras C, Gralec R, Cervesato E, Tomkowski W, DeBiasio M, Viel E, Bishiniotis T, Platogiannis DN, Buonadonna A, Tartuferi L, Piazza R, Tumolo S, Berretta M, Santini F, Imazio M. Neoplastic pericardial disease in lung cancer: impact on outcomes of different treatment strategies. A multicenter study. Lung Cancer 2011;72:340-347.
Sanz MA, Montesinos P. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. Blood 2014;123:2777-2782.
Shaheen S, Mirshahidi H, Nagaraj G, Hsueh CT. Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature. Exp Hematol Oncol 2018;7:11.
Sogaard KK, Farkas DK, Ehrenstein V, Bhaskaran K, Botker HE, Sorensen HT. Pericarditis as a marker of occult cancer and a prognostic factor for cancer mortality. Circulation 2017;136:996-1006.
Bogaert J, Cruz I, Voigt JU, Sinnaeve P, Imazio M. Value of pericardial effusion as imaging biomarker in acute pericarditis, do we need to focus on more appropriate ones? Int J Cardiol 2015;191:284-285.
Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Awadalla M, Hassan MZO, Moslehi JJ, Shah SP, Ganatra S, Thavendiranathan P, Lawrence DP, Groarke JD, Neilan TG. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 2018;71:1755-1764.
Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol 2018;19:e447-e58.
Ala CK, Klein AL, Moslehi JJ. Cancer treatment-associated pericardial disease: epidemiology, clinical presentation, diagnosis, and management. Curr Cardiol Rep 2019;21:156.
